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Case Series
Frequency of irregular Red Cell Alloantibodies in Patients with Thalassemia
Major: a Bicenter Study
Fareena Bilwani1, Ghulam Nabi Kakepoto1, Salman N. Adil1, Mohammad Usman1, Farrukh Hassan2, Mohammad Khurshid1
Department of Pathology, The Aga Khan University Hospital1 and Hussainy Blood Bank and Transfusion Centre, Karachi, Pakistan.

Abstract
Objective: To provide frequency and distribution pattern of various types of irregular red cell alloantibodies in
patients with thalassemia major.
Methods: This is a descriptive study conducted at two centers from January to December 2001. Purposive sampling was done and all patients diagnosed to have thalassemia major were included in the study. Antibody identification was carried out on serum employing commercial two-cell panel using standardized blood bank methods. If patients were found to have an irregular red cell alloantibody then the antibody identification was performed using 16 panel cells.
Results: A total of ninety-seven patients were included in the study. Fifty-three patients were males and 44
females. Mean age was 10.6 years. Irregular red cell alloantibodies were found in 9 (9.2%). Mean age of patients
who developed red cell alloantibody was 11.9 years. Three (33.3%) patients developed anti-K while two (22.2%)
had non-specific antibody. One patient each developed anti-D (11.1%) and anti-E (11.1%). Two had anti-D
(11.1%) and anti-C while the other one (11.1%) developed anti-E and anti-K.
Conclusion: We concluded that there is relatively high rate of alloimmunization in our set of patients when compared to data from our region. We also suggest that red cell alloimmunization should not be overlooked in
patients receiving regular blood transfusions (JPMA 55;563:2005).

Introduction
Appropriate and regular red cell transfusion remains
the main treatment choice for a large number of patients with
thalassemia major. These patients who are maintained on
hypertranfusion regimen can develop various complications
due to multiple transfusions, one of them being allosensitization to red cell antigens. As blood is routinely matched with
respect to major blood group antigens i.e. ABO and Rh D
antigen, there is a high probability that the donor will have
minor blood group antigens not present in the recipients
which will result in alloimmunization.
Alloimmunization significantly concerns the
Rhesus, Kell, Duffy and Kidd system which are clinically
significant.1 They can cause, not invariably haemolytic
transfusion reactions and limit the ability of safer transfusion while, others are clinically insignificant.1
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Factors for immunization are complex and involve at
least three main contributing elements. This includes RBC
antigenic difference between the blood donor and the recipient, the recipient's immune status and immunomodulatory
effect of the allogenic blood transfusions on the recipient's
immune system.2
In thalassemia major, red cell alloantibody production usually occurs after the age of 6 years after multiple transfusions. Perhaps this is due to immune tolerance developed by periodic blood transfusion started in
early age.3 The relation between the number of units of
blood transfused and antibody formation is unknown in
thalassemia major but it is an important factor for
increased alloimmunization. However, it has been said
that the earliest sensitization if any, appears usually after
ten transfusions.4
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The aim of this descriptive study is to provide frequency and distribution patterns of various types of irregular red cell alloantibodies in patients with thalassemia major
at two centers.

Patients and Methods
This is a case series conducted at two centers
from January to December 2001 using the purposive
sampling method.
All patients diagnosed to have thalassemia major on
haemoglobin electrophoresis were included in this study.
These patients were on hypertransfusion regimen, receiving
packed cells cross - matched for ABO and Rh D antigen.
Patients with any other haemoglobinopathy or
haematological disorder receiving multiple transfusions
were excluded from the study.
Informed consent was taken from all patients prior to
collection of blood sample. Antibody identification was carried out on serum employing two cell panel (Immucor, INC,
Norcross, GA, U.S.A.) using standardized blood bank methods.5 If patients were found to have an irregular red cell
alloantibody, then the antibody identification was performed
using 16 panel cells (Immucor, INC, Norcross, GA, U.S.A.).5
The variables noted were age, gender along with frequency and distribution of irregular red cell alloantibodies.
Also noted was the frequency of transfusion in patients who
developed irregular red cell alloantibodies.

Results
A total of ninety-seven patients diagnosed to have
thalassemia major were screened for the presence of red cell
alloantibodies. Forty-seven patients from Aga Khan
University Hospital and fifty patients enrolled at Hussainy
Blood Bank and Transfusion Center for regular blood transfusion were included in this study.
Fifty three (54.6%) patients were males and 44
(45.3%) were females. Mean age was 10.6 years (age range
2-24 years). All the patients were receiving blood transfusion at an interval of 2-4 weeks.
Irregular red cell alloantibodies were found in 9
(9.2%) patients. Mean age of patients who developed red
cell alloantibody was 11.9 years (range 2.5-24 years). Male
to female ratio was 2:1. Frequency of transfusion was 2-3
weeks in six (66.6%) patients while in three (3.33%)
patients it was 3-4 weeks.
Three (33.3%) patients developed anti-K while two
(22.2%) patients developed non-specific antibody. One
patient each developed anti-D (11.1%) and anti-E (11.1%).
Two patients developed two irregular red cell alloantibodies.
One patient (11.1%) developed anti-D and anti-C while the
other one (11.1%) developed anti-E and anti-K.
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Discussion
This study was conducted to demonstrate the frequency of irregular red cell alloantibodies in patients with
thalassemia major. In our study, the rate of development of
red cell alloimmunization is high (9.2 %) when compared to
another study from our region, which showed frequency of
irregular red cell alloantibodies to be 3.6%.2 The red cell
antibodies developed in this report were anti-Lewis a, antic, anti-N, anti-S, anti-C and anti-Fy, while our study
revealed red cell alloantibodies mainly from Rhesus and
Kell system.
Various centers all around the world have reported
different frequencies of immunization. The majority of
these reports have a high rate of alloimmunization but a few
centers have reported low rates when compared to our
data.2,4,6 Most of this published data have similar types of
irregular red cell alloantibodies as ours.
A study in Italy among patients of thalassemia major
by Sirchia et al3 revealed a rate of alloimmunization of
5.2% red cell alloantibodies were found in 74 out of 1432
patients. A total of 136 alloantibodies were found in 74
patients which were entirely confined to the common antigens of Rhesus, Kell, Kidd, Duffy and MNS system.
Twenty one (28%) patients had two alloantibodies and seventeen (23%) had more than two alloantibodies.
Another study conducted in Hong Kong among
patients of Asian descent by HOR - Kung Ho et al7 showed
a total of nine alloantibodies in 68 (7.4%) patients. The red
cell alloantibodies found were anti-E, anti-M, anti-HLA,
anti-BG, anti-BW 22. In this study anti-K was not encountered. This is in contrast to our data where anti-K was seen
in three patients.
However, many studies have also reported a high rate
of red cell alloimmunization. A study by Singer et al2, reported frequency of alloimmunization of 22% in patients with thalassemia major. He reported that 19 red cell alloantibodies
were seen in 14 out of 64 patients. Three antibodies were
detected in one patient while two antibodies in three patients.
Anti-Kell was most often identified. This report also interestingly states that patients who receive blood matched for
Rhesus and Kell system from their first transfusion, the rate of
alloimmunization is found to be relatively low. Hence they
inferred that transfusion of blood phenotypically matched for
Rh and Kell systems compared to blood phenotypically
matched for the standard ABO-RhD system could prove to be
effective in preventing alloimmunization.
Vasilikil Michail et al6 found rate of alloimmunization to be 19.16%, that is, 23 children developed alloantibodies out of 120 patients with thalassemia major receiving
regular blood transfusion. They reported alloimmunization
in two groups of children. One was the better-matched
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group which comprised of children who received blood
compatible with ABO, Cc, Ee, D and K antigen while the
usual-match group received blood compatible with ABO
and RhD antigen. They also found that the overall frequency of alloimmunization between the usual-match and better-match group was not statistically significant. In this
study, the antibodies belonged to Rhesus, Kell, Duffy,
Kidd, Lewis and MNS system. In the usual match group the
distribution frequency of alloantibodies was RhD: 35.8%,
Kell: 25.6%, Duffy: 10.2%, Kidd: 12.8% and MNSs and
Lewis: 7.6% each.
Spanos et al4 also found a high frequency of red
cell alloimmunization in 220 (22.6%) out of 973 thalassemic patients receiving blood matched for ABO and
RhD antigen. Alloantibodies belonged to the following
systems: 34% to Rhesus, 29.8% to Kell, 7.9% to MNS,
8.1% to Kidd, 6.6% to Bg, 5.9% to Lewis, 4.1% to Duffy
and 1.32% to P. Almost hald (51.8%) had formed only one
alloantibody and the rest (48.2%) produced more than one
antibody.
Hence we concluded that there is relatively high rate
of alloimmunization in our set of patients when compared
to data from our region. However more data is required
from various other large centers. We also concluded that
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red cell alloimmunization should not be overlooked in
patients with thalassemia major receiving regular blood
transfusion. It should always be considered if the patient
repeatedly suffers from haemolytic transfusion reaction or
not being able to maintain haemoglobin at a desired level
inspite of regular transfusions. Regular screening for red
cell alloantibodies would add towards the better management of these patients.
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